Skip to main content

Sanofi

13F filer · CIK 0001121404
Reported Jul 28, 2026
Net buyer this quarter
13F portfolio value$534MU.S. long equity reported on 13F
Positions102 new · 1 closed
Net flow last quarter+$22.9MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Jul 28, 202610 positions
MGTXMeiraGTx Holdings plc$165M30.86%12.95%Not reportedQ4 2024
INBXInhibrx Biosciences, Inc.$110M20.54%7.87%Not reportedQ4 2024
NVAXNovavax Inc$64.8M12.14%4.17%Not reportedQ4 2024
ANABAnaptysbio, Inc$55.5M10.39%2.82%-33.3%Q4 2024
ODTXOdyssey Therapeutics, Inc.$37.3M6.98%4.16%NewQ2 2026
AGMBAgomab Therapeutics NV$36.1M6.76%8.15%Not reportedQ1 2026
MPLTMapLight Therapeutics, Inc.$32.7M6.12%2.01%Not reportedQ4 2025
TRAXFirst Tracks Biotherapeutics, Inc.$16.5M3.10%2.32%NewQ2 2026
IMRXImmuneering Corp$13.5M2.53%10.44%Not reportedQ3 2025
QTTBQ32 Bio Inc.$3.11M0.58%1.03%Not reportedQ4 2024
Q1 2026Reported May 7, 20269 positions
MGTXMeiraGTx Holdings plc$106M31.44%14.98%Not reportedQ4 2024
INBXInhibrx Biosciences, Inc.$77.8M23.17%7.93%Not reportedQ4 2024
NVAXNovavax Inc$56M16.67%4.18%Not reportedQ4 2024
ANABAnaptysbio, Inc$30.4M9.04%2.83%Not reportedQ4 2024
AGMBAgomab Therapeutics NV$29.2M8.69%8.15%NewQ1 2026
MPLTMapLight Therapeutics, Inc.$18.5M5.52%2.02%Not reportedQ4 2025
IMRXImmuneering Corp$14.3M4.25%10.44%Not reportedQ3 2025
ELDNEledon Pharmaceuticals, Inc.$2.51M0.75%1.07%Not reportedQ4 2024
QTTBQ32 Bio Inc.$1.57M0.47%1.67%Not reportedQ4 2024
Q4 2025Reported Feb 11, 20268 positions
MGTXMeiraGTx Holdings plc$97M31.24%15.04%Not reportedQ4 2024
INBXInhibrx Biosciences, Inc.$91.5M29.47%7.94%Not reportedQ4 2024
NVAXNovavax Inc$46.2M14.90%4.23%Not reportedQ4 2024
ANABAnaptysbio, Inc$39.8M12.84%2.93%Not reportedQ4 2024
IMRXImmuneering Corp$17.8M5.74%10.44%Not reportedQ3 2025
MPLTMapLight Therapeutics, Inc.$16M5.16%2.07%NewQ4 2025
ELDNEledon Pharmaceuticals, Inc.$1.23M0.40%1.08%Not reportedQ4 2024
QTTBQ32 Bio Inc.$810K0.26%1.90%Not reportedQ4 2024
Q3 2025Reported Nov 4, 20259 positions
MGTXMeiraGTx Holdings plc$100M38.56%15.16%Not reportedQ4 2024
NVAXNovavax Inc$59.7M22.91%4.23%Not reportedQ4 2024
INBXInhibrx Biosciences, Inc.$39M14.98%7.99%Not reportedQ4 2024
ANABAnaptysbio, Inc$25.2M9.67%2.98%Not reportedQ4 2024
IMRXImmuneering Corp$19M7.28%10.44%NewQ3 2025
OMDAOmada Health, Inc.$11.6M4.46%0.91%Not reportedQ2 2025
LVTXLAVA Therapeutics NV$2.99M1.15%7.30%Not reportedQ4 2024
ELDNEledon Pharmaceuticals, Inc.$2.11M0.81%1.36%Not reportedQ4 2024
QTTBQ32 Bio Inc.$483K0.19%1.98%Not reportedQ4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.